Abstract
The objective of this study was to identify biologic parameters that were associated with either exceptionally good or poor outcome in childhood acute myeloid leukemia (AML). Among the children with AML who entered Children's Cancer Group trial 213, 498 patients without Down syndrome or acute promyelocytic leukemia (APL) comprise the basis for this report. Univariate comparisons of the proportion of patients attaining complete remission after induction (CR) indicate that, at diagnosis, male gender, low platelet count (⩽20 000/μl), hepatomegaly, myelodysplastic syndrome (MDS), French–American– British (FAB) category M5, high (>15%) bone marrow (BM) blasts on day 14 of the first course of induction, and +8 are associated with lower CR rates, while abnormal 16 is associated with a higher CR rate. Multivariate analysis suggests high platelet count at diagnosis (>20 000/μl), absence of hepatomegaly, ⩽15% day 14 BM blast percentage, and abnormal 16 are independent prognostic factors associated with better CR. Univariate analysis demonstrated a significant favorable relationship between platelet count at diagnosis (>20 000/μl), absence of hepatomegaly, low percentage of BM blasts (⩽15%), and abnormal 16 with overall survival. Absence of hepatomegaly, ⩽15% day 14 BM blast percentage, and abnormal 16 were determined to be independent prognostic factors associated with better survival.
Similar content being viewed by others
References
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia J Clin Oncol 1996 14: 18–24
Lampkin BC, Woods W, Strauss R, Feig S, Higgins G, Bernstein I, D'Angio G, Chard R, Bleyer A, Hammond D . Current status of the biology and treatment of acute non-lymphocytic leukemia in children (report from the ANLL strategy group of the Children's Cancer Study Group) Blood 1983 61: 215–228
Lampkin B, Wells R, Woods W, Ruymann F, Odom L, Benjamin D, Bernstein I, Betcher D, Versteeg C, Buckley J, Feig S, Kim T, Smithson W, Srivastava A, Tannous R, Whitt K, Wolff L, Krailo M, Hammond D . Preliminary results: Transplantation (BMT) vs intensification chemotherapy (Itf) and maintenance chemotherapy (M) vs no M in childhood acute non-lymphocytic leukemia (ANL) Proc Am Soc Clin Oncol 1990 9: 216
Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H . Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498 Blood 1992 80: 2210–2214
Grier HE, Gelber RD, Camitta BM, Delorey MJ, Link MP, Price KN, Leavitt PR, Weinstein HJ . Prognostic factors in childhood acute myelogenous leukemia J Clin Oncol 1987 5: 1026–1032
Creutzig U, Ritter J, Schellong G . Identification of two risk groups in childhood acute myelogenous leukemia after intensification in study AML-BFM-83 as compared with study AML-BFM-78 Blood 1990 75: 1932–1940
Amadori S, Ceci A, Comelli A, Madon E, Masera G, Nespoli L, Paolucci G, Zanesco L, Covelli A, Mandelli F . Treatment of acute myelogenous leukemia in children: results of the Italian Cooperative Study AIEOP/LAM 8204 J Clin Oncol 1987 5: 1356–1363
Kalwinsky DK, Raimondi SC, Schell MJ, Mirro J, Santana VM, Behm F, Dahl GV, Williams D . Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocyticleukemia J Clin Oncol 1990 8: 75–83
Woods WG, Nesbit ME, Buckley J, Lampkin BC, McCreadie S, Kim TH, Piomelli S, Kersey JH, Feig S, Bernstein I, Hammond D . Correlation of chromosome abnormalities with patient characteristics, histologic subtype, and induction success in children with acute nonlymphocytic leukemia J Clin Oncol 1985 3: 3–11
Buchner T, Heinecke A . The role of prognostic factors in acute myeloid leukemia Leukemia 1996 10 (Suppl. 1): S28–S29
Bloomfield CD . Prognostic factors for selecting curative therapy for adult myeloid leukemia Leukemia 1992 6 (Suppl. 4): 65–67
Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van Den Berghe H, Bloomfield CD, de la Chappelle A, Dewald G, Garson OM, Hagemeijer A, Mitelman F, Rowley JD, Sakurai M . Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia Cancer Genet Cytogenet 1994 73: 1–7
Schiffer CA . Acute myeloid leukemia in adults In: Holland JF, Bast RC Jr, Morton DL, Frei E, Kufe DW, Weichselbaum RR (eds) Cancer Medicine, 4th edn Williams & Wilkins: Baltimore 1996 pp 2617–2649
Wells RJ, Woods WG, Buckley JD, Odom LF, Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, Smithson W, Srivastava A, Tannous R, Buckley CM, Whitt JK, Wolff L, Lampkin BC . Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: a Childrens Cancer Group study J Clin Oncol 1994 12: 2367–2377
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Peto R, Peto J . Asymptotically efficient rank in variant test procedures JR Stat Soc A 1972 135: 185–206
Greenwood M . The errors of sampling of the survivorship tables. In: Reports on Public Health and Medical Subjects, No. 33, Appendix 1 His Majesty's Stationery Office: London 1926
Cox DR . Regression models and life tables (with discussion) JR Stat Soc B 1972 34: 187–220
Hirji KF, Mehta CR, Patel NR . Computing distributions for exact logistic regression JASA 1987 82: 1110–1117
Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG . Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891 Blood 1998 91: 608–615
Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, Weinstein HJ, Carroll AJ . Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study – POG 8821 Blood 1999 94: 3707–3716
Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S, Gold S, Barnard DR, DeSwarte J, Dusenbery K, Kalousek D, Arthur DC, Lange BJ . Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group Blood 1996 87: 4979–4989
Arthur DC, Berger R, Golomb HM, Swansbury GJ, Reeves BR, Alimena G, Van Den Berghe H, Bloomfield CD, de la Chapelle A, Dewald GW, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD . The clinical significance of karyotype in acute myelogenous leukemia Cancer Genet Cytogenet 1989 40: 203–216
Leblanc T, Auvrignon A, Michel G, Ansoborlo S, van den Akker J, Nelken B, Capodano A-M, Landman-Parker J, Baruchel A, Berger R, Schaison G, Leverger G . Prognosis value of cytogenetics in 250 children with acute myeloblastic leukemia treated in the LAME 89/91 protocol Blood 1996 88: 634a
Chang M, Raimondi SC, Ravindranath Y, Carroll AJ, Camitta B, Gresik MV, Steuber CP, Weinstein H . Prognostic factors in children and adolescents with acute myeloid leukemia (excluding patients with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) study 8821 Leukemia 2000 14: 1201–1207
Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Loffler H, Schellong G . Definition of a standard-risk group in children with AML Br J Haematol 1999 104: 630–639
Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JKH, Stevens RF, Walker H . A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties Br J Haematol 1999 107: 69–79
Martinez-Climent JA, Lane NJ, Rubin CM, Morgan E, Johnstone HS, Mick R, Murphy SB, Vardiman JW, Larson RA, LeBeau MM . Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo Leukemia 1995 9: 95–101
Acknowledgements
Contributing Children's Cancer Group investigators, institutions and grant numbers are given in the appendix. Grant support from the Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wells, R., Arthur, D., Srivastava, A. et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16, 601–607 (2002). https://doi.org/10.1038/sj.leu.2402390
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2402390
- Springer Nature Limited
Keywords
This article is cited by
-
Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards
Annals of Hematology (2014)
-
Hemophagocytic syndrome in children with acute monoblastic leukemia—another cause of fever of unknown origin
Supportive Care in Cancer (2013)
-
Prognostic Factors in Pediatric Acute Myeloid Leukemia
Current Hematologic Malignancy Reports (2010)
-
Interactive diagnostics in the indication to allogeneic SCT in AML
Bone Marrow Transplantation (2009)
-
Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891
Leukemia (2005)